Title |
Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
|
---|---|
Published in |
Pediatric Nephrology, April 2017
|
DOI | 10.1007/s00467-017-3672-x |
Pubmed ID | |
Authors |
Peter Janssens, Caroline Weydert, Stephanie De Rechter, Karl Martin Wissing, Max Christoph Liebau, Djalila Mekahli |
Abstract |
Polycystic kidney disease (PKD) encompasses a group of genetic disorders that are common causes of renal failure. The two classic forms of PKD are autosomal recessive polycystic kidney disease (ARPKD) and autosomal dominant polycystic kidney disease (ADPKD). Despite their clinical differences, ARPKD and ADPKD share many similarities. Altered intracellular Ca(2+) and increased cyclic adenosine monophosphate (cAMP) concentrations have repetitively been described as central anomalies that may alter signaling pathways leading to cyst formation. The vasopressin V2 receptor (V2R) antagonist tolvaptan lowers cAMP in cystic tissues and slows renal cystic progression and kidney function decline when given over 3 years in adult ADPKD patients. Tolvaptan is currently approved for the treatment of rapidly progressive disease in adult ADPKD patients. On the occasion of the recent initiation of a clinical trial with tolvaptan in pediatric ADPKD patients, we aim to describe the most important aspects in the literature regarding the AVP-cAMP axis and the clinical use of tolvaptan in PKD. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 1 | 9% |
Peru | 1 | 9% |
United Kingdom | 1 | 9% |
Brazil | 1 | 9% |
United States | 1 | 9% |
Venezuela, Bolivarian Republic of | 1 | 9% |
Unknown | 5 | 45% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 10 | 91% |
Science communicators (journalists, bloggers, editors) | 1 | 9% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 51 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 6 | 12% |
Student > Postgraduate | 5 | 10% |
Student > Bachelor | 5 | 10% |
Other | 4 | 8% |
Professor | 3 | 6% |
Other | 11 | 22% |
Unknown | 17 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 14 | 27% |
Biochemistry, Genetics and Molecular Biology | 4 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
Agricultural and Biological Sciences | 2 | 4% |
Nursing and Health Professions | 2 | 4% |
Other | 8 | 16% |
Unknown | 18 | 35% |